Skip to main content

Covishield For Covid-19 Gets Go Ahead From Committee, Over To Drug Regulator. 10 Points

360TotalSecurity WW

TRENDING NEWS -  COVID-19 VACCINE 

Dry run detailed steps shared by Dr Harsh Vardhan
from his Twitter handle @drharshvardhan

The Covishield vaccine candidate has received the green signal  from the Subject Expert Committee formed by the Drugs Controller General of India.

The first
Made In India vaccine, Covishield is manufactured by the Serum Institute of India (SII) at their Pune facility. It is developed by pharmaceutical company AstraZeneca and the University of Oxford.

The DCGI heads the Central Drugs Standard Control Organization of the Government of India. It is responsible for regulatory control and approval of serum or sera, clinical trials, new drugs, specific licenses and control over import of drugs among other functions.

Ajio [CPS] IN The CDSCO works under the guidance of the Ministry of Health and Family Welfare, currently led by Dr Harsh Vardhan.

What next?

The Subject Expert Committee, called the SEC has cleared the Covishield for emergency use, also known as Emergency Use Authorisation or Approval. 


The SEC has sent its recommendation to the DCGI who, as the final authority, will help ensure the vaccine is available nationwide.

The vaccine will be made available initially to priority groups such as our nation's frontline medical professionals who continue to treat the Covid-19 virus afflicted citizens despite risk to their own lives.

"The preparations are like general elections. The purpose of the dry run is to be ready for the actual rollout... Potential recipients of vaccine will be informed via SMS. Frontline workers are the priority. After inoculation, digital certificate will also be provided," NDTV quoted health minister Harsh Vardhan saying.

POINTS YOU NEED TO KNOW


  • India ranks as the country with the second-highest number of Covid-19 cases after the United States.
  • The Government of India aims to vaccinate 30 crore people in six to eight months, starting January 2021.
  • Serum Institute of India is the world's largest manufacturer of vaccines.
  • SII plans to roll out about 100 million vaccine shots by March, 2021.

  • Covishield is reported to be easier to transport and deliver at various centres in the country. It does not need extremely low temperatures for storage. It is also cheap and easy to mass-produce.

  • Covishield's testing involves 1600 volunteers as part of its phase 2 and 3 trials.
  • The Government of India plans to distribute the vaccines using the Covid Vaccine Intelligence Network (CoWIN) system. It's a digitalised platform that'll help roll out and scale up distribution of the vaccine.
  • CoWIN will also help track beneficiaries on a real-time basis.
  • Pre-registration is mandatory for Covid-19 vaccination.

    Bodyshop [CPV] IN




Comments

Popular posts from this blog

#INDvENG: 10 Aspects Team India May Need To Consider Ahead Of First Test Match In Chennai

 INDIA V ENGLAND - 1ST TEST, CHEPAUK, CHENNAI A behind-the-scenes peek at #TeamIndia 's fun photoshoot in whites ahead of the @Paytm #INDvENG Test series 🙌👌 pic.twitter.com/sQuRVKH5le — BCCI (@BCCI) February 4, 2021 PREVIEW   A lot has transpired since fortress Brisbane was breached. Most have moved on and are focusing on the new challenge.  Few, such as Team India's batting coach Vikram Rathour, are revisiting that victory to glean the positives and implement at home against a resurgent England .  However, if you consider returning captain Virat Kohli's statement on the eve of the Test saying "The focus will be on bowlers who can also bat," then Shardul Thakur and Washington Sundar  could be among the playing 11. This pair has been hailed by coach Ravi Shastri as the duo who broke the back of Australia in Brisbane.  It could be likely that both, Shastri and Kohli want these two to repeat that performance in Chennai when opportunity arrives and bre

#INDvENG: 5 Reasons Why India Failed Their One Square Root And Sibley Amazing Tests On Day 1

INDIA V ENGLAND - PAYTM TEST SERIES  REVIEW DAY ONE Cricket fans in India were expecting a Friday Blockbuster that'll see their Australia-triumph heroes, bowling or batting, put England on the back foot. Instead, the first day of the 4-Test series began with returning skipper Virat Kohli and his men failing to solve the square root of Joe test assigned to them. They failed even bigger when they allowed opener Dom Sibley to negotiate his way into form after struggling in Sri Lanka. Here are 5 reasons why Team India failed their test on Day 1:  1. Whose pitch is it anyway? It's a given that the host team prefers the curator of the pitch to prepare a deck that'll offer benefits to the home team from the start. Instead the Chepauk pitch was described by former England and India players now commentating as placid, flat, tepid, docile and probably every synonym that goes along.  It isn't clear as to why would the Board of Control for Cricket in India (BCCI) approve the

Bumrah's Cricket Rise With New RISE Worldwide Limited

  CRICKET CAPER  In Australia, much has been written about Will Pucovski and his penchant for big scores. The 22 year old, whose roots are from Czechoslovakia (his father migrated to Australia from Serbia), is a celebrity since his 62 on debut against India in the third Test match at the SCG on January 7, 2021. Team India's net bowler and aspiring senior team prospect, Kartik Tyagi continues to be apologetic after his delivery hit Pucovski's helmet during a tour match early December 2020. Tyagi's worry is genuine considering all pace bowlers are aware of Phil Hughes' fate. Pucovski recovered successfully from his concussion to hit that 62. A few days ago, he told The Grade Cricketer that facing India's ace pace star Japsrit Bumrah first ball on debut reminded him of playing a PlayStation game   during his   school days . "I actually genuinely felt like I was playing a PlayStation game , it was like International Cricket 2011 or something on PlayStation .